Immuneering Corporation (IMRX)
1.44
-0.07 (-4.64%)
At close: Apr 04, 2025, 3:49 PM
-4.64% (1D)
| Bid | 1.41 |
| Market Cap | 51.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.04 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | -1.18 |
| Analyst | Buy |
| Ask | 1.44 |
| Volume | 139,787 |
| Avg. Volume (20D) | 1,743,804 |
| Open | 1.47 |
| Previous Close | 1.51 |
| Day's Range | 1.41 - 1.50 |
| 52-Week Range | 1.00 - 3.83 |
| Beta | -0.26 |
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 66
Stock Exchange NASDAQ
Ticker Symbol IMRX
Website https://immuneering.com
Analyst Forecast
According to 2 analyst ratings, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 768.06% from the latest price.
Stock Forecasts2 weeks ago
+9.09%
Immuneering shares are trading higher. Needham rei...
Unlock content with
Pro Subscription
2 months ago
+0%
Immuneering shares are trading higher after the company released interim data from its Phase 2a trials of IMM-1-104 and IMM-6-415 in advanced RAS and RAF-mutant tumors.
